AIDS Treatment News
Statement of Purpose
AIDS Treatment News is one of the primary treatment resources for community-based organizations and government agencies. Because of the insightful articles presented in each newsletter, case workers and counselors are consistently able to recommend AIDS Treatment News to their clients.
Physicians, counselors, and clinicians are among the many professionals who regularly turn to AIDS Treatment News for accurate, timely reporting. The New York Times, The Wall Street Journal, Cable News Network, Journal of the American Medical Association, and ABC and CBS News have all depended on AIDS Treatment News for vital information about the many facets of the AIDS epidemic.
AIDS Treatment News keeps you informed of public-policy developments, whether they involve changes in clinical trials or the drug-approval process. The newsletter can help you learn how to overcome obstacles in obtaining medication, and provides news about the prevention of illnesses commonly associated with HIV. AIDS Treatment News is your opportunity to have the latest information on AIDS treatments and public policy delivered directly to you, twice each month. Each issue will give you insight into treatments and options currently in use by physicians, and other medical professionals and people with AIDS/HIV. AIDS Treatment News is dedicated to giving you a thoroughly accurate publication with a style of writing that is useful for physicians, but accessible to people living with AIDS/HIV.
AIDS Treatment News
Published twice monthly, 24 times per year, on the first and third Friday of every month. Print copies are sent by first class mail. E-mail is available. Back issues are available.
Subscription and Editorial Office:
AIDS Treatment News
1233 Locust St., 5th floor
Philadelphia, PA 19107
800/804-8845 toll-free U.S. and Canada
215/546-3776 regular office number
e-mail: email@example.com or firstname.lastname@example.org
useful links: www.aidsnews.org
Editor and Publisher:
John S. James
Jennifer Cohn, Tadd T. Tobias, R.N.
Businesses, Institutions, Professionals: $325/year.
Nonprofit organizations: $150/year.
Individuals: $140/year, or $80 for six months. If you cannot afford a subscription, please write or call about our sliding scale.
Business, nonprofit, and full-rate individual subscribers can receive an early copy by e-mail, before the issue is printed, in addition to their regular copy at no extra charge. It's okay to direct the e-mail copy to someone else. Call our office to add e-mail to your subscription.
Outside North, Central, or South America, add air mail postage:
$20/year, $10 for six months.
Back issues available.
Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details.
Please send U.S. funds: Personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, American Express, and purchase orders also accepted.
Free e-mail: Free delivery for individuals (delayed one week). To subscribe, send a blank e-mail to: email@example.com.
Notice: AIDS Treatment News gladly provides its information without charge on the Internet. Since we began in January 1987, we have been supported only by subscriptions. We ask those in a position to do so to consider helping us meet expenses by subscribing to the printed edition of the newsletter, available world wide by first class mail/airmail.
Alternatively, you can help by making a tax-deductible contribution to AIDS Treatment News Associates. For more information, see AIDS Treatment News Associates (ATNA) Receives Nonprofit Status in AIDS Treatment News Issue #254, September 6, 1996. Or call Kevin Farrell, 415/241-0413, or Denny Smith, 415/750-4852.
ISSN # 1052-4207
Copyright 2003 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
Latest by AIDS Treatment News
Summary: KP-1461, an experimental HIV drug already in a phase II trial, works so differently from other antiretrovirals that at first glance it looked like science fiction, and we found it hard to take seriously as a current possibility today. In fac...
AIDS Treatment News publishes a buyers' club list each December. For a short overview and introduction to the meaning, history, and services of these organizations, see AIDS Treatment News #309, December 18, 1998.
All the organizations listed below ...
The FDA has asked the pharmaceutical industry for help in testing technology to track drugs electronically through the supply chain to prevent drug counterfeiting -- a huge worldwide problem that mushroomed in the U.S. several years ago, centered esp...
Many thousands of people could not continue filling even their current prescriptions after the new Medicare Part D (prescription drug coverage) started January 1, 2006. Many thousands are wrongly being told to pay hundreds of dollars, when they are o...
Today's pharmaceutical research and development has two huge problems, one widely recognized and the other often missed.
1. New-Drug Prices
Under the current system most of the world's people will have no access to new, patented drugs for up to 20...
Tipranavir (brand name Aptivus), a protease inhibitor that usually works against HIV that is resistant to other protease inhibitors, was recommended for approval by the FDA's Antiviral Drugs Advisory Committee at a meeting on May 19, 2005. The drug, ...
Each month, almost 700 low-income Americans living with HIV apply to become clients of the AIDS Drug Assistance Program (ADAP), which pays for anti-HIV medications to treat those without health insurance (or without adequate coverage). Unlike with Me...
Years ago Hoffmann-LaRoche (now Roche) developed an experimental drug that blocked the HIV protein Tat in laboratory tests. But it did not work against HIV in patients, for reasons that were then unknown. Though scientists considered this kind of ant...
This study of kidney and liver transplantation for persons with HIV, by 19 transplant centers with funding from the U.S. National Institutes of Health, is currently running and is open for new people. Even for patients who do not need a transplant im...
Sculptra (Formerly New Fill) for Facial Wasting -- Where to Find Information on the Patient-Assistance Program
SculptraTM (marketed in some countries as New FillTM) was approved in August 2004 by the FDA "for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus." It was approved narrowly for t...